Research Paper Volume 13, Issue 3 pp 4468—4481

PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades

Inhibition of PRMT5 suppresses cell growth and cell cycle progression. HCT116, SW480, and FHC cells are treated with different doses and time points of GSK591, a PRMT5 specific inhibitor. (A) The global symmetric dimethylarginine (SDMA) is detected by Western blotting. Representative data is shown. (B) Cell viability is measured during different time points in HCT116 and FHC cells (n=4). *P C) Cell viability is measured in HCT116 and FHC cells with different doses of GSK591 (n=4). *P D) Immunostaining of ki67 in HCT116 cells treated with GSK591. Scale bar = 50μm. (E) Western blot analysis of cyclin D1, cyclin E1, and p27 protein expression level in HCT116 and SW480 cells. Representative data is shown. (F–H) Indicated proteins are quantified in HCT116 and SW480 cells. *P

Figure 3. Inhibition of PRMT5 suppresses cell growth and cell cycle progression. HCT116, SW480, and FHC cells are treated with different doses and time points of GSK591, a PRMT5 specific inhibitor. (A) The global symmetric dimethylarginine (SDMA) is detected by Western blotting. Representative data is shown. (B) Cell viability is measured during different time points in HCT116 and FHC cells (n=4). *P < 0.05 vs. DMSO treatment. (C) Cell viability is measured in HCT116 and FHC cells with different doses of GSK591 (n=4). *P < 0.05 vs. FHC cells. (D) Immunostaining of ki67 in HCT116 cells treated with GSK591. Scale bar = 50μm. (E) Western blot analysis of cyclin D1, cyclin E1, and p27 protein expression level in HCT116 and SW480 cells. Representative data is shown. (FH) Indicated proteins are quantified in HCT116 and SW480 cells. *P < 0.05 vs. DMSO.